OS Therapies Incorporated (OSTX)

Market Cap	36.11M
Revenue (ttm)	n/a
Net Income (ttm)	-7.42M
Shares Out	21.24M
EPS (ttm)	-0.76
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	372,203
Open	1.890
Previous Close	1.890
Day's Range	1.700 - 1.970
52-Week Range	1.580 - 7.000
Beta	n/a
Analysts	Strong Buy
Price Target	17.50 (+929.41%)
Earnings Date	Mar 4, 2025

About OSTX

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Mary...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 1, 2024
• Employees: 4
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: OSTX
• Website: https://ostherapies.com

Analyst Forecast

According to 2 analysts, the average rating for OSTX stock is "Strong Buy." The 12-month stock price forecast is $17.5, which is an increase of 929.41% from the latest price.

Price Target

$17.5

(929.41% upside)

Analyst Consensus: Strong Buy